Menu
Not yet recruiting NCT07702734

Dietary Pattern Intervention for Neurodevelopment in Preterm Infants

No phase Interventional Preterm Neurodevelopmental Disorders Dysbiosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Structured High-Prebiotic Dietary Pattern.
Who it may be relevant to
Registry conditions: Preterm, Neurodevelopmental Disorders, Dysbiosis. Basic parameters: 6 months — 6 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of Gut Microbiota Remodeling Via Structured Prebiotic Dietary Pattern on Neurodevelopment in Preterm Infants: A Randomized Controlled Trial

Overview

The purpose of this randomized controlled trial is to evaluate the effect of a structured, high-prebiotic dietary pattern on the neurodevelopmental outcomes of preterm infants. The intervention lasts for 6 months and aims to promote the growth of endogenous beneficial gut bacteria through targeted complementary feeding. The primary outcome is assessed by the Gesell Developmental Schedules or the Ages \& Stages Questionnaires (ASQ-3). Secondary outcomes include longitudinal changes in gut microbiota composition,targeted metabolomics (such as short-chain fatty acids and tryptophan metabolites), and systemic inflammatory markers.

Detailed description

Preterm infants frequently face early-life gut dysbiosis due to perinatal complications and antibiotic exposure, which may adversely affect their neurodevelopment via the microbiota-gut-brain axis. While exogenous probiotics are one approach, modulating the gut microbiota through endogenous substrates-specifically, structured dietary interventions-offers a sustainable and highly translational alternative.

This single-blind, randomized controlled trial aims to evaluate the efficacy of a structured, high-prebiotic complementary feeding pattern on neurodevelopmental outcomes. Eligible preteum infants (aged 6 to 12 months, corrected age) will be randomized into the dietary intervention group or the standard care control group. Families in the intervention group will receive individualized, face-to-face guidance and tailored recipes from a registered dietitian, focusing on the scientific introduction of prebiotic-rich complementary foods according to the infant's age. The intervention spans 6 months.

Outcomes will be evaluated using the Gesell Developmental Schedules or ASQ-3. Concurrently, fecal and blood samples will be collected to analyze the dynamic shifts in gut microbiota composition and key metabolic pathways . This study will help elucidate whether structured dietary patterns can effectively reshape the gut microbiota and confer neuroprotective benefits in preterm infants.

Interventions

  • Behavioral Structured High-Prebiotic Dietary Pattern
    Individualized, face-to-face guidance and tailored recipes provided by a registered dietitian, focusing on the scientific introduction of prebiotic-rich complementary foods to promote endogenous beneficial gut bacteria over a 6-month period.

Primary outcome measures

  • Neurodevelopmental Status Assessed by the Gesell Developmental Schedules (GDS) [Time frame: Baseline and 6 months post-intervention]
Secondary outcome measures (5)
  • Parent-Reported Neurodevelopment Assessed by the Ages and Stages Questionnaires, Third Edition (ASQ-3) [Time frame: Baseline and 6 months post-intervention]
  • Change in Fecal Short-Chain Fatty Acid (SCFA) Concentrations Assessed by Gas Chromatography-Mass Spectrometry (GC-MS) [Time frame: Baseline, 3 months, and 6 months post-intervention]
  • Change in Fecal Tryptophan-Indole Derivatives Assessed by Liquid Chromatography-Mass Spectrometry (LC-MS) [Time frame: Baseline, 3 months, and 6 months post-intervention]
  • Change in Systemic Inflammatory Cytokine Levels Assessed by Enzyme-Linked Immunosorbent Assay (ELISA) [Time frame: Baseline, 3 months, and 6 months post-intervention]
  • Change in Gut Microbiota Alpha Diversity (Shannon Index) Assessed by 16S rRNA Sequencing [Time frame: Baseline and 6 months post-intervention]

Eligibility criteria

Inclusion criteria

  • Preterm infants with a gestational age between 28 and 37 weeks (inclusive of 28 weeks)
  • Documented history of neonatal intravenous antibiotic exposure for at least 5 consecutive days during the neonatal period (e.g., in the NICU).
  • Corrected age of 6 months ± 7days at the time of enrollment.
  • No systemic antibiotic usage within 14 days prior to screening.
  • Legal guardians are willing to sign the informed consent form and comply with the 6-month intervention and follow-up schedule.

Exclusion criteria

  • Severe congenital malformations, chromosomal abnormalities, or inherited metabolic diseases (e.g., Down syndrome).
  • Severe neurological disorders or structural brain injuries (e.g., Grade III/IV intraventricular hemorrhage, cystic periventricular leukomalacia, or hydrocephalus requiring a shunt).
  • Severe chronic diseases affecting growth and development (e.g., congenital heart disease requiring surgery, short bowel syndrome, or severe sequelae of necrotizing enterocolitis).
  • Concurrent participation in other interventional clinical trials.
  • Planned long-term use of other commercial probiotic/prebiotic supplements outside the study protocol during the intervention period.
  • High risk of loss to follow-up (e.g., expected relocation).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Prevention

Study locations

China · 1 center
  • Shanghai Children's Hospital — Shanghai

Identifiers

NCT: NCT07702734 · 2026R020- F02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗